Literature DB >> 22935455

Vascular endothelial growth factor and survivin immunostaining in gastric adenocarcinoma.

Jarosław Bury1, Justyna Szumiło, Andrzej Dąbrowski, Aleksander Ciechański, Justyna Śliwińska, Grzegorz Wallner.   

Abstract

UNLABELLED: Two molecules - vascular endothelial growth factor involved in new vessels formation and survivin - antiapoptotic protein, reported to be associated with worse prognosis in various malignancies have been chosen for the study. Both are potential target for novel therapies. THE AIM OF THE STUDY: Was to determine the immunostaining of VEGF and survivin in gastric carcinoma and to analyse their relationship to the selected clinicopathological features and survival.
MATERIAL AND METHODS: Formalin-fixed, paraffin-embedded sections from 41 gastric adenocarcinomas were used for immunohistochemical reaction with monoclonal antibodies against vascular endothelial growth factor and survivin. The results were compared with selected clinicopathological features and survival.
RESULTS: Positive immunohistochemical reaction for vascular endothelial growth factor and survivin was revealed in 24 (58,53%) and 30 (73,17%), gastric carcinomas respectively. Vascular endothelial growth factor-negative gastric carcinomas were significantly more common in cases without metastases to regional lymph nodes and distant organs and in less advanced cases. Similar, distant metastases were also statistically less common in survivin-negative carcinomas. The differences in immunohistochemical reactions for survivin between less and more advanced cases almost reach statistical significance. The only factors significantly influenced 1, 2 and 3-year survival were vascular endothelial growth factor and survivin status. Statistically significant higher percentage of survival was noted in patients with vascular endothelial growth factor- and survivin-negative tumors.
CONCLUSIONS: It seems that vascular endothelial growth factor and survivin play role in local invasion and spread of gastric adenocarcinoma and negatively influences survival. However, further studies are required to assess their true usefulness in the clinical practice.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22935455     DOI: 10.2478/v10035-012-0057-5

Source DB:  PubMed          Journal:  Pol Przegl Chir        ISSN: 0032-373X


  4 in total

1.  Role of survivin as prognostic and clinicopathological marker in gastric cancer: a meta-analysis.

Authors:  Andreas Krieg; Billur Baseras; Monika Tomczak; Pablo Emilio Verde; Nikolas Hendrik Stoecklein; Wolfram Trudo Knoefel
Journal:  Mol Biol Rep       Date:  2013-08-15       Impact factor: 2.316

2.  Survivin and XIAP expression in distinct tumor compartments of surgically resected gastric cancer: XIAP as a prognostic marker in diffuse and mixed type adenocarcinomas.

Authors:  Levent Dizdar; Monika Tomczak; Thomas A Werner; Sami A Safi; Jasmin C Riemer; Pablo E Verde; Nikolas H Stoecklein; Wolfram T Knoefel; Andreas Krieg
Journal:  Oncol Lett       Date:  2017-09-19       Impact factor: 2.967

3.  EXPRESSION OF E-CADHERIN AND WNT PATHWAY PROTEINS BETACATENIN, APC, TCF-4 AND SURVIVIN IN GASTRIC ADENOCARCINOMA: CLINICAL AND PATHOLOGICAL IMPLICATION.

Authors:  Rodrigo Rego Lins; Celina Tizuko Fujiyama Oshima; Levindo Alves de Oliveira; Marcelo Souza Silva; Ana Maria Amaral Antonio Mader; Jaques Waisberg
Journal:  Arq Bras Cir Dig       Date:  2016 Nov-Dec

Review 4.  Prognostic value of survivin in patients with gastric cancer: a systematic review with meta-analysis.

Authors:  Jin Long Liu; Wei Gao; Qing Min Kang; Xue Jun Zhang; Shu Guang Yang
Journal:  PLoS One       Date:  2013-08-02       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.